References and Notes
1a
Tellitu I.
Serna S.
Herrero MT.
Moreno I.
Domínguez E.
SanMartin R.
J.
Org. Chem.
2007,
72:
1526
1b
Serna S.
Tellitu I.
Domínguez E.
Moreno I.
SanMartin R.
Org.
Lett.
2005,
7:
3073
2
Tellitu I.
Urrejola A.
Serna S.
Moreno I.
Herrero MT.
Domínguez E.
SanMartin R.
Correa A.
Eur. J. Org. Chem.
2007,
437
3
Pardo LM.
Tellitu I.
Domínguez E.
Tetrahedron
2010,
66:
5811
4
Pardo LM.
Tellitu I.
Domínguez E.
Synthesis
2010,
971
5a
Díaz L.
Bujons J.
Casas J.
Llebaria A.
Delgado A.
J. Med. Chem.
2010,
53:
5248
5b
Asano N.
Nash RJ.
Molyneux RJ.
Fleet GWJ.
Tetrahedron:
Asymmetry
2000,
11:
1645
5c
Sinnott ML.
Chem. Rev.
1990,
90:
1171
6a
Platt FM.
Neises GR.
Reinkensmeier G.
Townsend MJ.
Perry VH.
Proia RL.
Winchester B.
Dwek RA.
Butters TD.
Science
1997,
276:
428
6b
Nojima H.
Kimura I.
Chen F.-J.
Sugihara Y.
Haruno M.
Kato A.
Asano N.
J.
Nat. Prod.
1998,
61:
397
7a
Goss PE.
Baker MA.
Carver JP.
Dennis JW.
Clin. Cancer Res.
1995,
1:
935
7b
Pili R.
Chang J.
Partis RA.
Mueller RA.
Chrest FJ.
Passaniti A.
Cancer
Res.
1995,
55:
2920
8a
De Clercq E.
Med. Res. Rev.
2000,
20:
323
8b
Winkler DA.
Holan G.
J. Med. Chem.
1989,
32:
2084
For reviews on availability, synthesis,
and biological evaluation of polyhydroxylated indolizidines, see:
9a
Gupta P.
Pal APJ.
Reddy YS.
Vankar YD.
Eur. J.
Org. Chem.
2011,
1166
9b
El Nemr AE.
Tetrahedron
2000,
56:
8579
9c
Burgess K.
Henderson I.
Tetrahedron
1992,
48:
4045
9d See also ref. 5b.
For some recent representative
examples, including references therein, see:
10a
Kamal A.
Vangala SR.
Tetrahedron
2011,
67:
1341
10b
Hu X.-G.
Bartholomew B.
Nash RJ.
Wilson FX.
Fleet GWJ.
Nakagawa S.
Kato A.
Jia Y.-M.
van Well R.
Yu C.-Y.
Org. Lett.
2010,
12:
2562
10c
Izquierdo I.
Tamayo JA.
Rodríguez M.
Franco F.
Lo Re D.
Tetrahedron
2008,
64:
7910
10d
Karanjule NS.
Markad SD.
Shinde VS.
Dhavale DD.
J.
Org. Chem.
2006,
71:
4667
11a
Paolucci C.
Mattioli L.
J.
Org. Chem.
2001,
66:
4787 ; and
ref. 9 cited therein
11b
Lindsay KB.
Pyne SG.
J.
Org. Chem.
2002,
67:
7774 ;
and ref. 3 cited therein
11c
Carretero JC.
Arrayas RG.
J.
Org. Chem.
1998,
63:
2993 ;
and ref. 6 cited therein
12a
Zambrano V.
Rassu G.
Roggio A.
Pinna L.
Zanardi F.
Curti C.
Casiraghi G.
Battistini L.
Org.
Biomol. Chem.
2010,
8:
1725
12b
Tian Y.-S.
Joo J.-E.
Kong B.-S.
Pham V.-T.
Lee K.-Y.
Ham W.-H.
J. Org. Chem.
2009,
74:
3962
12c
Alam MA.
Kumar A.
Vankar YD.
Eur. J. Org. Chem.
2008,
4972
12d
Shi G.-F.
Li J.-Q.
Jiang
X.-P.
Cheng Y.
Tetrahedron
2008,
64:
5005
12e
Abrams JN.
Babu RS.
Guo H.
Le D.
Le J.
Osbourn JM.
O’Doherty GA.
J. Org. Chem.
2008,
73:
1935
12f
Guo H.
O’Doherty GA.
Tetrahedron
2008,
64:
304
12g
Bi J.
Aggarwal VK.
Chem. Commun.
2008,
120
12h
Ceccon J.
Greene AE.
Poisson J.-F.
Org.
Lett.
2006,
8:
4739
12i
Michael JP.
Nat. Prod. Rep.
2008,
25:
139
13 The selection of the E/Z mixture of 3 was
made on the basis of economic reasons with respect to both expensive
isolated stereoisomers. Moreover, it was anticipated that an E/Z mixture
of (±)-6 should render the same
compound after the ring-closing-metathesis step. All these compounds
(4-6) were
prepared as E/Z isomers
and no effort to isolate them was attempted.
14 For a useful review on the Sonogashira
reaction, see: Chinchilla R.
Nájera C.
Chem. Rev.
2007,
107:
874
The putative syn stereochemistry
of (±)-6 was assumed, but not
confirmed, on the basis of some related reports:
15a
Yun JM.
Sim TB.
Hahm HS.
Lee WK.
Ha
H.-J.
J. Org. Chem.
2003,
68:
7675
15b
Kim BC.
Lee WK.
Tetrahedron
1996,
52:
12117 ; to the view of the undesired results in
its transformation into (±)-7,
in which the tetrahedral carbinol group becomes trigonal, no additional
effort to clarify the stereochemical relationships in (±)-6 or (±)-7 was
carried out.
16
Grubbs RH.
Trnka TM.
Ruthenium-Catalyzed
Olefin Metathesis, In Ruthenium in Organic
Synthesis
Murahashi S.
Wiley-VCH;
Weinheim:
2004.
p.153-177
17
Chowdhury S.
Roy S.
J. Org. Chem.
1997,
62:
199
The development of protecting-group-free
syntheses must be a mandatory impulse for all synthetic organic
chemists. See, for example:
18a
Young IS.
Baran PS.
Nat.
Chem.
2009,
1:
193
18b
Hoffmann RW.
Synthesis
2006,
3531
18c
Baran PS.
Maimone TJ.
Richter JM.
Nature (London)
2007,
446:
404
18d
Roulland E.
Angew.
Chem. Int. Ed.
2011,
50:
1226 ;
and references therein
19 For a description of the combined
use of several dihydroxylation methods, see: Reddy JS.
Rao BV.
J.
Org. Chem.
2007,
72:
2224
20 A combination of NOESY, selective
COSY, and HMBC experiments were carried out to establish the stereochemical relationships
in compounds (±)-12a,b and (±)-13a.
From these results, the relative stereochemistry in (±)-11a,b was inferred.
21
Representative
Procedure for the PIFA-Mediated Heterocyclization: Synthesis of(
rac
)-
N
-Allyl-5-(3-phenylacryloyl)pyrrolidin-2-one [(±)-10]
A
solution of alkynylamide 9 (885 mg, 3.7
mmol) in CF3CH2OH (30 mL) was stirred at 0 ˚C,
and a solution of PIFA (2.3 g, 5.5 mmol) in 25 mL of the same solvent
was added dropwise. The reaction mixture was stirred at that temperature
for 2 h. For the workup, aq Na2CO3 (20%,
30 mL) was added, and the mixture was extracted with CH2Cl2 (2 × 40
mL). The combined organic layers were washed with brine, dried over
Na2SO4, and the solvent evaporated. Purification
of the crude by flash chromatography (EtOAc) gave pyrrolidinone
as a chromatographically pure yellowish oil (74%). Following
the representative procedure, pyrrolidinone (±)-10 was obtained from 9 (74%)
and purified by flash chromatography (EtOAc) as a yellowish oil. ¹H
NMR (300 MHz, CDCl3): δ = 7.70 (d, J = 15.8 Hz,
1 H), 7.54-7.39 (m, 5 H), 6.76 (d, J = 15.8
Hz, 1 H), 5.75-5.62 (m, 1 H), 5.15-5.08 (m, 2
H), 4.53-4.41 (m, 2 H), 3.46-3.38 (m, 1 H), 2.48-2.33
(m, 3 H), 2.00-1.93 (m, 1 H) ppm. ¹³C NMR
(300 MHz, CDCl3): δ = 197.2, 175.2,
145.2, 133.9, 132.1, 131.2, 129.1, 128.6, 121.4, 118.8, 63.7, 44.5,
29.6, 21.4 ppm. IR: ν = 1692, 1609 (CO) cm-¹.
HRMS: m/z calcd for C16H17NO2˙H+:
256.1338; found: 256.1335.
Representative
Procedure for the L-Selectride Reductive Step: Synthesis of
rac
-(5
R
,1′
R
)-
N
-Allyl-5-(1-hydroxy-3-phenylallyl)pyrrolidin-2-one [(±)-11a]
A
solution of L-Selectride® (1.8 mL, 1.0 M in
THF) was added dropwise to a cold (-78 ˚C) solution
of pyrrolidinone (±)-10 (230 mg,
0.9 mmol) in 4.5 mL of the same solvent. After 30 min, the temperature
was raised to r.t. and 2 mL of an aq solution of NaOH (10%)
was added. The whole mixture was extracted with CH2Cl2 (3 × 10
mL), the combined organic layers were dried over Na2SO4,
and the solvent evaporated. Purification of the crude by flash chromatography
(EtOAc) gave pyrrolidinone (±)-11a as
a chromatographically pure yellowish oil (70%). ¹H
NMR (300 MHz, CDCl3): δ = 7.30-7.17
(m, 5 H), 6.59 (d, J = 15.9 Hz,
1 H), 6.10 (dd, J = 15.9,
6.0 Hz, 1 H), 5.72-5.65 (m, 1 H), 5.14 (d, J = 4.5 Hz,
1 H), 5.10 (s, 1 H), 4.39-4.25 (m, 2 H), 3.76-3.64
(m, 2 H), 2.88 (br s, 1 H), 2.36-1.98 (m, 4 H) ppm. ¹³C
NMR (300 MHz, CDCl3): δ = 175.9, 136.2,
132.8, 132.3, 128.7, 128.0, 127.5, 126.5, 117.8, 73.4, 61.6, 44.7, 30.2,
20.5 ppm. IR: ν = 3374, 1670 cm-¹.
HRMS: m/z calcd for C16H19NO2˙H+:
258.1494; found: 258.1507.
Representative
Procedure for the Dihydroxylation Step: Synthesis of
rac
-(6
S
,7
S
,8
S
,9
R
)-6,7,8-Trihydroxyhexahydroindolizidin-3-one [(±)-13a]
K2OsO4˙2H2O
(7 mg, 0.015 mmol) and N-methyl-morpholine-N-oxide (70 mg, 0.6 mmol) were sequentially added
to 2 mL of an acetone-H2O (1:1) solution of indolizidinone
(±)-12a (50 mg, 0.3 mmol). The
mixture was stirred at r.t. for 18 h, and then filtered through
Celite. The volatiles were eliminated, and the residue was column chromatographed
(EtOAc) to render trihydroxyindolizi-dinone (±)-13a as a colorless oil (93%). ¹H
NMR (300 MHz, MeOD): δ = 5.48 (d, J = 3.7 Hz,
1 H), 3.94-3.64 (m, 3 H), 2.49-2.29 (m, 2 H),
2.11-1.87 (m, 4 H) ppm. ¹³C
NMR (300 MHz, MeOD): δ = 177.5, 74.5, 68.2, 65.0,
57.2, 35.2, 32.5, 19.6 ppm. IR: ν = 3408, 1660
cm-¹. HRMS: m/z calcd
for C8H13NO4˙H+:
188.0923; found: 188.0915.